945397-14-8

Usage

Organic compound

A compound primarily made up of carbon, hydrogen, and other elements such as nitrogen, oxygen, and sulfur.

Piperazine class of chemicals

A group of chemical compounds that consist of a six-membered heterocyclic ring structure, with two nitrogen atoms at adjacent positions.

Piperazine ring

A six-membered ring structure in the compound, formed by five carbon atoms and one nitrogen atom.

Methyl group at the 1-position

A single carbon atom bonded to three hydrogen atoms, attached to the first position of the piperazine ring.

Sulfone group at the 4-position

An organic functional group consisting of a sulfur atom double-bonded to two oxygen atoms, attached to the fourth position of the piperazine ring.

Nitrophenyl group at the 3-position

An organic functional group containing a phenyl ring with a nitro group (-NO2) attached to the third position of the piperazine ring.

Methyl group attached to the sulfone group

A single carbon atom bonded to three hydrogen atoms, connected to the sulfur atom in the sulfone group.

Potential applications in pharmaceutical research

The compound's structural features and properties make it a candidate for further study in the development of new drugs and therapies.

Ability to target specific biological receptors or enzymes

The compound may interact with specific proteins or enzymes in the body, which could be exploited for therapeutic purposes.

Synthesis and characterization

The process of creating and identifying the structure and properties of the compound through scientific studies.

Biological activities and medicinal properties

The potential effects the compound may have on living organisms and its possible use in the treatment or prevention of diseases.

Upstream product

• 3819-88-3 1-fluoro-3-iodo-5-nitrobenzene 
• 109-01-3 1-methyl-piperazine 
• 7087-27-6 1-fluoro-3-(methylsulfonyl)-5-nitrobenzene 

Downstream Products

• 945397-20-6 3-(4-methylpiperazin-1-yl)-5-(methylsulfonyl)aniline 

Relevant academic research and scientific papers

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors

Janus kinases (JAKs) have been demonstrated to be critical in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases. The JAK family consists of four highly homologous members: JAK1-3 and TYK2. The development of small-m

PYRIMIDINE DERIVATIVES

The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

NOVEL PYRIMIDINE DERIVATIVES 698

The invention concerns compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, n, R2, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.